Search our collection

Clear all filters
Category
Object type
Material
Maker
Place
Date
Patient information letter inviting participation in an expanded STI571 clinical trial issued to Doreen Eggleton being treated for Chronic Myeloid Leukaemia (CML), by Hammersmith Hospital in 2001. The letter is titled: 'An expanded access protocol of (clinical trial) STI571 in patients with Chronic myeloid leukaemia (CML) who are hematologically or cytogentically resistant or refractory to Interferon-Alpha or intolerant of Interferon-Alpha'.

Patient information about expanding the UK clinical trial of Glivec (imatinib), 2001

2001
Patient information letter titled 'Background information and current status of imintib mesylate - clinical usage and licensing (also known as STI571, Glivec, Gleevec)', issued to Doreen Eggleton being treated for Chronic Myeloid Leukaemia (CML), by Hammersmith Hospital, dated August 2001. Summarising information about the Glivec (imatinib) drug trials, cost of the drug made by Novartis, and actions leading to the drug becoming available on the NHS.

Patient information letter about the targeted cancer drug Glivec being made available on the NHS, 2001.

2001
Patient information documents related to the Co-vax Covid-19 research study (CML-CO-VAX - Seroprotection against SARS-CoV-2 in Chronic Myeloid Leukaemia (CML) patients receiving TKI therapy), inviting CML patient Doreen Eggleton to participate, issued by Imperial College Healthcare NHS Trust, 30th July 2022. Includes schedule for vaccination and assessment tests.

Patient information letter relating to Co-vax Covid-19 research study, 2021

2021
Patient information letter inviting participation in the STI571 clinical trial of the drug Glivec (imatinib) in adult patients patients with Chronic Myeloid Leukemia (CML), issued to Doreen Eggleton being treated for CML, issued by Hammersmith Hospital in 2001.

Patient information about UK clinical trial of Glivec (imatinib), 2001

2001